Citations 471

Comparison of variables associated with cerebrospinal fluid neurofilament, total‐tau, and neurogranin

Alzheimer's & Dementia | October 23, 2019 | Volume: 15 | Issue: 11 | Pages: 1437-1447

10.1016/j.jalz.2019.07.009 | PMID 31668594

Abstract Introduction Three cerebrospinal fluid (CSF) markers of neurodegeneration (N) (neurofilament light [NfL], total‐tau [T‐tau], and neurogranin [Ng]) have been proposed under the AT(N) scheme of the National Institute on Aging–Alzheimer's Association Research Framework. Methods We examined, in a community‐based population (N = 777, aged 50–95) (1) what variables were associated with each of the CSF (N) markers, and (2) whether the variables associated with each marker differed by increased brain amyloid. CSF T‐tau was measured with an automated electrochemiluminescence Elecsys immunoassay; NfL and Ng were measured with in‐house enzyme‐linked immunosorbent assays. Results Multiple variables were differentially associated with CSF NfL and T‐tau levels, but not Ng. Most associations were attenuated after adjustment for age and sex. T‐tau had the strongest association with cognition in the presence of amyloidosis, followed by Ng. Variables associations with NfL did not differ by amyloid status. Discussion Understanding factors that influence CSF (N) markers will assist in the interpretation and utility of these markers in clinical practice.
IC‐P‐086: CORTICAL ATROPHY PATTERNS OF EMPIRICALLY DERIVED INCIDENT MCI SUBTYPES IN THE MAYO CLINIC STUDY OF AGING

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2019.06.4929

IC‐P‐065: ANALYSIS OF IOFLUPANE‐SPECT FINDINGS USING DATQUANT IN PATIENTS WITH IDIOPATHIC REM SLEEP BEHAVIOR DISORDER

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2019.06.4908

IC‐P‐064: ANALYSIS OF IOFLUPANE‐SPECT FINDINGS USING DATQUANT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2019.06.4907

O4‐03‐03: CLINICAL CHARACTERIZATION OF MILD COGNITIVE IMPAIRMENT ASSOCIATED WITH EVENTUAL LEWY BODY DISEASE PATHOLOGY

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_23 | Pages: No page available

10.1016/j.jalz.2019.06.4754

O3‐04‐01: BIOMARKERS FOR CAPTURING AMYLOID‐INDEPENDENT EFFECTS OF VASCULAR HEALTH ON COGNITIVE DECLINE

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2019.06.4642

O2‐11‐01: CROSS‐SECTIONAL ASSOCIATIONS BETWEEN CSF BIOMARKERS OF AMYLOID AND TAU WITH NEUROPSYCHIATRIC SYMPTOMS: THE MAYO CLINIC STUDY OF AGING

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_11 | Pages: No page available

10.1016/j.jalz.2019.06.4511

O2‐03‐05: PREVALENCE OF CLINICALLY VERSUS BIOLOGICALLY DEFINED ALZHEIMER'S SPECTRUM ENTITIES USING THE NATIONAL INSTITUTE ON AGING – ALZHEIMER'S ASSOCIATION RESEARCH FRAMEWORK

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2019.06.4467

IC‐P‐160: STRESS: BETTER COPING ASSOCIATED WITH LOWER TAU IN PRECLINICAL ALZHEIMER'S DISEASE

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2019.06.4275

P4‐330: LONGITUDINAL BEHAVIOR OF BETA‐AMYLOID IN NEURODEGENERATIVE DEMENTIAS

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_27 | Pages: No page available

10.1016/j.jalz.2019.06.4000